Luis de la Cruz‐Merino

机构：Hospital Universitario Virgen Macarena, Instituto de Biomedicina de Sevilla, Spanish Head & Neck Cancer Cooperative Group, Universidad de Sevilla · ORCID：0000-0002-5333-0535

发表论文 348 篇 · 总被引 13941 次 · h-index 44

代表论文

• Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review (2025 · Frontiers in Immunology · 被引 37)
• IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages (2025 · Nature Cancer · 被引 30)
• Nivolumab for Resected Stage III or IV Melanoma at 9 Years (2025 · New England Journal of Medicine · 被引 24)
• BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203 (2025 · Journal of Clinical Oncology · 被引 12)
• Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy (2025 · ImmunoTargets and Therapy · 被引 7)
• 1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma (2025 · Annals of Oncology · 被引 2)